Haveli Investment Management LLC Purchases Shares of 7,400,000 Certara, Inc. $CERT

Haveli Investment Management LLC acquired a new position in shares of Certara, Inc. (NASDAQ:CERT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,400,000 shares of the company’s stock, valued at approximately $48,470,000,000. Certara makes up approximately 26.9% of Haveli Investment Management LLC’s portfolio, making the stock its 2nd biggest holding. Haveli Investment Management LLC owned 4.85% of Certara as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CERT. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after purchasing an additional 2,870 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares during the last quarter. State of Wyoming bought a new position in Certara during the 2nd quarter valued at about $72,000. Finally, Pacer Advisors Inc. boosted its position in Certara by 28.1% in the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock valued at $75,000 after buying an additional 2,871 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Craig Hallum decreased their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. Barclays boosted their target price on Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Stephens dropped their price target on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Robert W. Baird reduced their price objective on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 12th. Finally, Morgan Stanley decreased their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.28.

Certara Price Performance

CERT opened at $8.14 on Wednesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55. The stock has a market capitalization of $1.24 billion, a P/E ratio of -18.09 and a beta of 1.44. The company’s 50 day simple moving average is $7.21 and its 200-day simple moving average is $6.45. Certara, Inc. has a one year low of $4.45 and a one year high of $13.88.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.07 EPS. Sell-side analysts anticipate that Certara, Inc. will post 0.22 earnings per share for the current fiscal year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.